Market Cap : 202.49 M | Enterprise Value : 133.28 M | PE Ratio : At Loss | PB Ratio : 3.04 |
---|
NAS:VTGN has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NAS:VTGN has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Total Debt per Share is calculated as total debt divided by Shares Outstanding (EOP). Total debt is calculated as Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. VistaGen Therapeutics's Total Debt Per Share for the quarter that ended in Mar. 2022 was $0.02.
The historical data trend for VistaGen Therapeutics's Total Debt per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VistaGen Therapeutics's Total Debt Per Share for the fiscal year that ended in Mar. 2022 is calculated as:
Total Debt Per Share | = | (Long-Term Debt & Capital Lease Obligation | + | Short-Term Debt & Capital Lease Obligation) | / | Shares Outstanding (EOP) |
= | (2.61 | + | 0.43) | / | 206.54 | |
= | 0.01 |
VistaGen Therapeutics's Total Debt Per Share for the quarter that ended in Mar. 2022 is calculated as:
Total Debt Per Share | = | (Long-Term Debt & Capital Lease Obligation | + | Short-Term Debt & Capital Lease Obligation) | / | Shares Outstanding (EOP) |
= | (2.61 | + | 0.43) | / | 206.54 | |
= | 0.01 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of VistaGen Therapeutics's Total Debt per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Saxe Jon S | director | FIRST HORIZON PHARMACEUTICAL CORP 660 HEMBREE PKWY STE 106 ROSWELL GA 30076 |
Dotson Jerrold Duane | officer: VP, CFO AND SECRETARY | 5 CENTERPOINTE DRIVE SUITE 400 LAKE OSWEGO OR 97035 |
Singh Shawn | director, officer: CHIEF EXECUTIVE OFFICER | C/O VISTAGEN THERAPEUTICS, INC. 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080 |
Snodgrass H. Ralph | director, officer: PRES./CHIEF SCIENTIFIC OFFICER | 384 OYSTER POINT BLVD. SUITE 8 SOUTH SAN FRANCISCO CA 94080 |
Smith Mark Alan | officer: CHIEF MEDICAL OFFICER | 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080 |
Mcpartland Mark A. | officer: VP CORPORATE DEVELOPMENT | C/O VISTAGEN THERAPEUTICS, INC. 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080 |
Gin Jerry B | director | 343 ALLERTON AVE SOUTH SAN FRANCISCO CA 94080 |
Underdown Brian J. | director | C/O LUMIRA CAPITAL INVESTMENT MANAGEMENT 141 ADELAIDE ST. WEST, SUITE 770 TORONTO ONTARIO CANADA M5H 3L5 A6 00000 |
Cunningham Ann Michelle | director | 255 N CALDWELL CIRCLE DOWNINGTOWN PA 19335 |
Rice A. Franklin | officer: VP CORPORATE DEVELOPMENT | 384 OYSTER POINT BLVD. SUITE 8 SOUTH SAN FRANCISCO CA 94080 |
Bonfiglio Gregory A. | director | 384 OYSTER POINT BOULEVARD, NO. 8 SOUTH SAN FRANCISCO CA 94080 |
Platinum Long Term Growth Vii, Llc | 10 percent owner | 152 WEST 57TH STREET 4TH FLOOR NEW YORK NY 10019 |
Cato Holding Co | 10 percent owner | 4364 SOUTH ALSTON AVENUE DURHAM NC 27713 |
Cato Allen Easley | 10 percent owner | 4364 SOUTH ALSTON AVENUE DURHAM NC 27713 |
Jones Stephanie | director, 10 percent owner, officer: PRESIDENT | 13834 W. HOYT ROAD RATHDRUM ID 83858 |
From GuruFocus
Other Sources
By Fool 2021-06-30
By Seekingalpha 2021-06-29
By Zacks 2021-03-11
By Zacks 2021-10-20
By Seekingalpha 2021-01-24
By tipranks.com 2022-03-03
By tipranks.com 2022-02-13
By Seekingalpha 2022-02-10
By Zacks 2021-11-10
By Seekingalpha 2021-11-10
By Zacks 2021-08-12
By Zacks 2022-02-10
By Zacks 2021-02-11
By Zacks 2021-06-16